Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Pipeline Review, H2 2017
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Pipeline Review, H2 2017
SUMMARY
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Bromodomain Containing Protein 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 4 and 2 respectively. Report covers products from therapy areas Oncology, Immunology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Follicular Lymphoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Lung Cancer, Malignant Pleural Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis (Scleroderma).
Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Bromodomain Containing Protein 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 4 and 2 respectively. Report covers products from therapy areas Oncology, Immunology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Follicular Lymphoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Lung Cancer, Malignant Pleural Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis (Scleroderma).
Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
- The report reviews Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
Merck & Co Inc
Nuevolution AB
Trillium Therapeutics Inc
Zenith Epigenetics Ltd
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles
birabresib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-0610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FT-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-7770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6146 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-281 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones
Featured News & Press Releases
Oct 27, 2017: Nuevolution to present new data on its BET BD1 program supporting the understanding of the biological mode-of-action
Aug 24, 2017: Cancer Drug Can Reactivate HIV
Jul 05, 2017: Trillium Provides Update on Preclinical Development Program, TTI-281
Jun 19, 2017: Nuevolution Presents Additional Positive Animal Results in Lupus From its BET Selective Program
Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
Dec 14, 2016: Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694
Sep 16, 2016: Presentation of preclinical data on its BET BD1 program at Discovery on Target 2016
Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details
Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies
Mar 18, 2015: New Data Investigating Merck’s MK-8628 in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
Nov 12, 2014: Oncoethix Starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)
Nov 20, 2013: Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer
Sep 10, 2013: Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma
Jan 31, 2013: OncoEthix Doses First Patient In Phase I Trial Of OTX015 For Treatment Of Hematologic Malignancies
Nov 29, 2012: Cancer Drug Shows Promise In Eradicating Latent HIV Infection, Research Shows
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
Merck & Co Inc
Nuevolution AB
Trillium Therapeutics Inc
Zenith Epigenetics Ltd
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles
birabresib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-0610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FT-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-7770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6146 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-281 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones
Featured News & Press Releases
Oct 27, 2017: Nuevolution to present new data on its BET BD1 program supporting the understanding of the biological mode-of-action
Aug 24, 2017: Cancer Drug Can Reactivate HIV
Jul 05, 2017: Trillium Provides Update on Preclinical Development Program, TTI-281
Jun 19, 2017: Nuevolution Presents Additional Positive Animal Results in Lupus From its BET Selective Program
Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
Dec 14, 2016: Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694
Sep 16, 2016: Presentation of preclinical data on its BET BD1 program at Discovery on Target 2016
Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details
Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies
Mar 18, 2015: New Data Investigating Merck’s MK-8628 in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
Nov 12, 2014: Oncoethix Starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)
Nov 20, 2013: Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer
Sep 10, 2013: Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma
Jan 31, 2013: OncoEthix Doses First Patient In Phase I Trial Of OTX015 For Treatment Of Hematologic Malignancies
Nov 29, 2012: Cancer Drug Shows Promise In Eradicating Latent HIV Infection, Research Shows
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by Forma Therapeutics Inc, H2 2017
Pipeline by Merck & Co Inc, H2 2017
Pipeline by Nuevolution AB, H2 2017
Pipeline by Trillium Therapeutics Inc, H2 2017
Pipeline by Zenith Epigenetics Ltd, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by Forma Therapeutics Inc, H2 2017
Pipeline by Merck & Co Inc, H2 2017
Pipeline by Nuevolution AB, H2 2017
Pipeline by Trillium Therapeutics Inc, H2 2017
Pipeline by Zenith Epigenetics Ltd, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
Merck & Co Inc
Nuevolution AB
Trillium Therapeutics Inc
Zenith Epigenetics Ltd
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
Merck & Co Inc
Nuevolution AB
Trillium Therapeutics Inc
Zenith Epigenetics Ltd
